{"entity":{"id":"spry2","kind":"target","name":"SPRY2","aka":["sprouty RTK signaling antagonist 2","Protein sprouty homolog 2","hSPRY2"],"tldr":"SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","summary":"Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2. Thereby acts as an antagonist of FGF-induced retinal lens fibre differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis. Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:11270","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11270"},{"label":"UniProt O43597","url":"https://www.uniprot.org/uniprotkb/O43597/entry"},{"label":"NCBI Gene 10253","url":"https://www.ncbi.nlm.nih.gov/gene/10253"},{"label":"Ensembl ENSG00000136158","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136158"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"SPRY2","role":["biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:11270","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11270","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O43597","url":"https://www.uniprot.org/uniprotkb/O43597/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene SPRY2","url":"https://civicdb.org/features/8160","note":"1 evidence items, 0 assertions, 1 variants; diseases: Gastric Adenocarcinoma (GraphQL API, CC0)"}],"hgnc":"HGNC:11270","ensembl":"ENSG00000136158","uniprot":"O43597","entrez":"10253","biology":"Antagonist of fibroblast growth factor (FGF) pathways via inhibition of FGF-mediated phosphorylation of ERK1/2. Thereby acts as an antagonist of FGF-induced retinal lens fibre differentiation, may inhibit limb bud outgrowth and may negatively modulate respiratory organogenesis. Inhibits TGFB-induced epithelial-to-mesenchymal transition in retinal lens epithelial cells. Inhibits CBL/C-CBL-mediated EGFR ubiquitination. Location: Cytoplasm, cytoskeleton; Cell projection, ruffle membrane (UniProt). Locus 13q31.1 (HGNC).","whereFound":["Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/spry2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}]}}